SOMATULINE DEPOT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOMATULINE DEPOT (SOMATULINE DEPOT).
Somatostatin analog; binds to somatostatin receptors (mainly SSTR2 and SSTR5) with high affinity, inhibiting the secretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), and various gastrointestinal hormones.
| Metabolism | Hepatic via CYP450 isoenzymes; primarily excreted unchanged in bile. |
| Excretion | Lanreotide is primarily excreted via the biliary-fecal route. After administration, approximately 78% of a radiolabeled dose is recovered in feces, with less than 5% excreted unchanged in urine. The remainder is metabolized and eliminated via bile. |
| Half-life | The terminal elimination half-life is approximately 23-29 days after subcutaneous injection of the depot formulation, supporting a monthly dosing interval. |
| Protein binding | 88-90% bound primarily to alpha-1-acid glycoprotein (AAG), with minor binding to albumin. |
| Volume of Distribution | 15-30 L, reflecting extensive tissue distribution. Given a typical body weight of 70 kg, this corresponds to approximately 0.21-0.43 L/kg. |
| Bioavailability | Subcutaneous injection: Approximately 80% (range 68-96%) relative to intravenous administration. The depot formulation provides sustained release over 28 days. |
| Onset of Action | Subcutaneous injection: Clinical suppression of growth hormone and IGF-1 levels is observed within 1-2 weeks after the first injection, with maximal effect by 4 weeks. |
| Duration of Action | Subcutaneous injection: The therapeutic effect persists for approximately 4 weeks after a single dose, consistent with the monthly dosing interval. |
| Molecular Weight | 1082.24 |
90 mg subcutaneously every 4 weeks for acromegaly; 120 mg subcutaneously every 4 weeks for neuroendocrine tumors (administered every 2 weeks if progression occurs). Adjust dose based on clinical response and growth hormone/IGF-1 levels.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment recommended for GFR ≥30 mL/min; for GFR <30 mL/min, use with caution and monitor for adverse effects due to limited data - consider dose reduction or interval prolongation. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 60 mg every 4 weeks; Child-Pugh C: not recommended (no data). |
| Pediatric use | Not approved for patients <18 years; safety and efficacy not established. No weight-based dosing guidelines available. |
| Geriatric use | No specific dose adjustment based on age alone; consider age-related renal function decline and monitor renal status; initiate at lower end of dosing range due to potential for increased sensitivity. |
| 1st trimester | Avoid use due to potential fetal risk; animal studies show adverse effects. |
| 2nd trimester | Avoid use unless benefit outweighs risk; limited human data. |
| 3rd trimester | Avoid use as it may affect fetal growth and development. |
Clinical note
Comprehensive clinical and safety monograph for SOMATULINE DEPOT (SOMATULINE DEPOT).
| Placental transfer | Unknown but likely crosses placenta due to peptide nature; no human data. |
| Breastfeeding | No lactation studies available; somatuline depot is not recommended during breastfeeding due to potential drug excretion and effects on infant. |
| Lactation Rating |
■ FDA Black Box Warning
Not applicable
| Serious Effects |
Hypersensitivity to lanreotide or any component of the formulation
| Precautions | Gallbladder abnormalities (gallstones), Hypoglycemia/hyperglycemia, Cardiac conduction abnormalities, Pituitary apoplexy, Vitamin B12 deficiency, Thyroid function disturbances, Bradycardia |
| Food/Dietary | Grapefruit juice may increase lanreotide exposure. No other significant food interactions. Avoid alcohol if liver impairment exists. No specific dietary restrictions otherwise. |
| Clinical Pearls |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Pregnancy Category X. Animal studies have shown embryotoxicity and teratogenicity. There is no adequate data in pregnant women; the drug is contraindicated during pregnancy due to risk of fetal harm. In first trimester, potential for major malformations; second and third trimesters may affect fetal growth and development. |
| Fetal Monitoring | Monitor pregnancy status before and during therapy. Ultrasound for fetal growth and development if inadvertent exposure occurs. Maternal monitoring includes liver function tests, blood glucose, gallbladder ultrasound, and ECG for QT prolongation. |
| Fertility Effects | May impair fertility in females due to suppression of gonadotropin secretion; effects are reversible upon discontinuation. In males, reduced sperm production and testicular atrophy have been observed in animal studies. |
| Somatuline Depot (lanreotide) is a somatostatin analog for acromegaly and neuroendocrine tumors. Administer deep subcutaneous injection into the superior outer quadrant of the buttock; rotate sites. Monitor for gallbladder sludge/stones, bradycardia, and glucose levels. Avoid in patients with untreated biliary obstruction. Dose adjustment not needed in renal impairment but caution in severe hepatic impairment. |
| Patient Advice | Avoid grapefruit juice as it may increase drug levels. · Report severe abdominal pain, jaundice, or signs of cholelithiasis. · Monitor blood sugar regularly; may cause hyper- or hypoglycemia. · Do not rub injection site; apply cold compress for discomfort. · Missed dose: administer next scheduled dose; do not double. |